TrkC 詳細
Molecule Name
Neurotrophic tyrosine kinase receptor type 3
分子の別称
NT-3 growth factor receptor,GP145-TrkC,Neurotrophic tyrosine kinase receptor type 3, TrkC tyrosine kinase
Drug Development Progress
治験薬の数6
市販薬剤の数4
研究＆開発段階Approved
ターゲットの別称
NT-3 growth factor receptor，TrkC tyrosine kinase，Neurotrophic Receptor Tyrosine Kinase 3，Neurotrophic Tyrosine Kinase， Receptor， Type 3，EC:2.7.10.1，GP145-TrkC，TRKC，EC 2.7.10，ETS Related Protein-Neurotrophic Receptor Tyrosine Kinase Fusion Protein，Neurotrophic Tyrosine Kinase Receptor Type 3，Tyrosine Kinase Receptor C，ETV6-NTRK3 Fusion，Trk-C，NTRK3，Gp145(TrkC)，EC 2.7.10.1，Receptor， trkC
バックグランド
Tropomyosin receptor kinase C (TrkC), also known as NT-3 growth factor receptor, neurotrophic tyrosine kinase receptor type 3, or TrkC tyrosine kinase is a protein that in humans is encoded by the NTRK3 gene. It belongs to the tropomyosin-related kinase (Trk) family of receptor tyrosine kinases (TrkA, TrkB, and TrkC).
TrkC is the high affinity catalytic receptor for the neurotrophin NT-3 (neurotrophin-3). As such, TrkC mediates the multiple effects of this neurotrophic factor, which includes neuronal differentiation and survival.
TrkC 製品リスト
You Have Viewed 0 Of 0 Results
治験薬に関する情報
| 英語名 | 研究コード | 研究開発ステージ | 会社 | 適応症 | 臨床試験 |
|---|---|---|---|---|---|
| Lestaurtinib | SPM-924; A-154475.0; KT-5555; SP-924; CEP-701 | Phase 3 Clinical | Kyowa Hakko Kirin Co Ltd | Bone Marrow Neoplasms; Leukemia; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Neuroblastoma; Polycythemia Vera; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Primary Myelofibrosis; Prostatic Neoplasms; Psoriasis; Thrombocythemia, Essential | 詳細 |
| Merestinib | 5OGS5K699E; LY-2801653 | Phase 2 Clinical | Eli Lilly And Company | Biliary Tract Neoplasms; Bone metastases; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cholangiocarcinoma; Colorectal Neoplasms; Gallbladder Neoplasms; Leukemia, Myeloid, Acute; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Microsatellite instability-high cancer; Neoplasm Metastasis; Neoplasms; Pancreatic Neoplasms; Skin Melanoma; Solid tumours | 詳細 |
| FCN-011 | FCN-011 | Phase 2 Clinical | Solid tumours | 詳細 | |
| Emzeltrectinib | CT-3417; TQB-3558 | Phase 1 Clinical | Beijing Centaurus Biopharma Co Ltd, Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd | Solid tumours | 詳細 |
| HG-030 | HG-030 | Phase 1 Clinical | Hitgen Inc | Solid tumours | 詳細 |
| Paltimatrectinib | PBI-200 | Phase 1 Clinical | Pyramid Biosciences | Brain Neoplasms; Desmoplastic Small Round Cell Tumor; Solid tumours | 詳細 |
市販薬剤に関する情報
| 英語名 | 研究コード | 研究開発ステージ | 会社 | オリジナル製品名 | 最初に承認をした国 | 最初の適応症 | 最初に承認を受けた会社 | 承認された日付 | 適応症 | 臨床試験 |
|---|---|---|---|---|---|---|---|---|---|---|
| Taletrectinib Adipate | DS-6051b; DS-6051a; DS-6051; AB-106; IBI-344 | Approved | Daiichi Sankyo Co Ltd | 达伯乐, DOVBLERON, IBTROZI | Mainland China | Carcinoma, Non-Small-Cell Lung | AnHeart Therapeutics Co Ltd | 2024-12-17 | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Metastatic breast cancer; Neoplasms; Solid tumours | 詳細 |
| Entrectinib | NMS-E628; RXDX-101; RG-6268 | Approved | Nerviano Medical Sciences Srl | Rozlytrek, 罗圣全 | Japan | Carcinoma, Non-Small-Cell Lung | Chugai Pharmaceutical Co Ltd | 2019-06-18 | Brain Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Central Nervous System Neoplasms; Cholangiocarcinoma; Colorectal Neoplasms; Glioma; Head and Neck Neoplasms; Hematologic Neoplasms; Hepatic Insufficiency; Leukemia, Myeloid, Acute; Lymphoma, Large-Cell, Anaplastic; Lymphoproliferative Disorders; Melanoma; Neoplasms; Neuroendocrine Tumors; Ovarian Neoplasms; Pancreatic Neoplasms; Salivary Gland Neoplasms; Sarcoma; Solid tumours; Thyroid Cancer, Papillary | 詳細 |
| Larotrectinib sulfate | LOXO-101; ARRY-470; BAY-2757556 | Approved | Array Biopharma | Vitrakvi, 维泰凯 | United States | Solid tumours | Bayer Healthcare | 2018-11-26 | Breast Neoplasms; Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Central Nervous System Neoplasms; Colonic Neoplasms; Colorectal Neoplasms; Endometrial Neoplasms; Ependymoma; Esophageal Neoplasms; Fibrosarcoma; Glioma; Head and Neck Neoplasms; Hematologic Neoplasms; Hepatoblastoma; Histiocytic Sarcoma; Histiocytosis, Langerhans-Cell; Leukemia; Liver Neoplasms; Lung Neoplasms; Lymphoma; Lymphoma, Non-Hodgkin; Medulloblastoma; Melanoma; Multiple Myeloma; Neoplasms; Neoplasms, Germ Cell and Embryonal; Neuroblastoma; Neuroectodermal Tumors, Primitive, Peripheral; Osteosarcoma; Ovarian Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms; Rectal Neoplasms; Rhabdoid Tumor; Rhabdomyosarcoma; Sarcoma; Sarcoma, Ewing; Skin Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Thyroid Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Uterine Neoplasms; Wilms Tumor; Xanthogranuloma, Juvenile | 詳細 |
| Repotrectinib | TPX-0005; BMS-986472; ZL-2308 | Approved | Turning Point Therapeutics Inc | Augtyro, 奥凯乐 | United States | Carcinoma, Non-Small-Cell Lung | Bristol-Myers Squibb Company | 2023-11-15 | Brain metastases; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Hepatic Insufficiency; Lymphoma; Neoplasms; Solid tumours | 詳細 |